^
    Apply
    Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer (ToPCourT) (NCT06027268)
    Phase 2
    Wake Forest University Health Sciences
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    01/10/2024
    Primary completion :
    09/01/2026
    Completion :
    03/01/2027
    HER-2 • PD-L1
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • Cosela (trilaciclib)
    I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2) (NCT01042379)
    Phase 2
    QuantumLeap Healthcare Collaborative
    Recruiting
    Last update posted :
    10/22/2024
    Initiation :
    03/01/2010
    Primary completion :
    12/01/2030
    Completion :
    12/01/2031
    HER-2 • ER
    |
    ER positive • ER negative
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1
    A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients (NCT06569485)
    Phase 2
    Sun Yat-sen University
    Recruiting
    Last update posted :
    08/26/2024
    Initiation :
    05/23/2024
    Primary completion :
    12/30/2024
    Completion :
    12/01/2027
    CD8 • IFNG • CDK4 • IL2RA • CD4 • IL2 • FOXP3 • IL17A • ISG20
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Cosela (trilaciclib)
    Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer (NCT05112536)
    Phase 2
    G1 Therapeutics, Inc.
    Completed
    Last update posted :
    03/12/2024
    Initiation :
    03/03/2022
    Primary completion :
    10/31/2022
    Completion :
    03/13/2023
    ER • PGR • CD8
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Cosela (trilaciclib) • cyclophosphamide intravenous
    Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) (PRESERVE 2) (NCT04799249)
    Phase 3
    G1 Therapeutics, Inc.
    Active, not recruiting
    Last update posted :
    01/15/2024
    Initiation :
    04/15/2021
    Primary completion :
    06/30/2024
    Completion :
    10/25/2024
    HER-2 • PGR
    |
    PD-L1 expression • HER-2 negative
    |
    carboplatin • gemcitabine • Cosela (trilaciclib)
    Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy (SMA-BC-002) (NCT05978648)
    Phase 2
    wang shusen
    Recruiting
    Last update posted :
    11/30/2023
    Initiation :
    09/20/2023
    Primary completion :
    12/31/2026
    Completion :
    12/31/2027
    HER-2 • ER • PGR
    |
    HER-2 positive • HER-2 negative • ER negative • HER-2 negative + HR negative
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • cyclophosphamide • epirubicin • Cosela (trilaciclib)
    Study of Trilaciclib and Lurbinectidin (NCT05578326)
    Phase 2
    UNC Lineberger Comprehensive Cancer Center
    Recruiting
    Last update posted :
    11/16/2023
    Initiation :
    10/12/2022
    Primary completion :
    07/25/2024
    Completion :
    07/25/2026
    PD-L1
    |
    Zepzelca (lurbinectedin) • Cosela (trilaciclib)
    The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC (NCT05862610)
    Phase 2
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Un...
    Not yet recruiting
    Last update posted :
    07/24/2023
    Initiation :
    07/30/2023
    Primary completion :
    12/30/2026
    Completion :
    06/30/2027
    HER-2
    |
    HER-2 overexpression • HER-2 negative
    |
    albumin-bound paclitaxel • cyclophosphamide • epirubicin • Cosela (trilaciclib)